Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
Newsroom
InvestorsPress releases

Back
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
 3:00:00 PM

Keep reading
Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)Read